Case Study:
Biovaccines Nigeria Limited – Building Nigeria’s Local Vaccine Production Capability
Client Overview
- Website: (Minimal landing page at bio-vaccine; limited functionality requiring JavaScript) (Biovaccines Nigeria Limited)
- Industry: Pharmaceutical / Vaccine Manufacturing (Public–Private Partnership)
- Location: Yaba, Lagos, Nigeria
- Founded: 2005 (may-baker.com, LinkedIn)
- Mission: To develop, produce, and distribute safe, affordable human vaccines in Nigeria; reduce mortality from vaccine-preventable diseases; establish a regional vaccine production hub; and enhance Nigeria’s role in the global vaccine industry (may-baker.com, LinkedIn).
Project Overview
Biovaccines Nigeria Limited (BVNL) was created via a joint venture between May & Baker Nigeria Plc (51%) and the Federal Government of Nigeria (49%) to reactivate local vaccine production—particularly using the legacy facilities in Yaba—and to position Nigeria as a self-reliant vaccine manufacturer in West Africa (may-baker.com, Premium Times Nigeria, The Nation Newspaper).
Challenges
- Dormant Infrastructure: The historic Federal Vaccine Production Laboratory (in Yaba) had been inactive for decades (closed since the early 1990s) (The Nation Newspaper).
- Global Dependence: Nigeria was heavily reliant on imported vaccines, resulting in supply vulnerabilities and higher costs.
- Operational Readiness: Constructing a state-of-the-art facility and transferring vaccine manufacturing technology presented logistical and regulatory hurdles.
Solutions Implemented
- Joint Venture Formation: Established BVNL in 2005 as a public–private partnership to revive vaccine production capabilities (may-baker.com, Premium Times Nigeria).
- Government & Industry Collaboration: Secured Federal Executive Council approval in September 2022 for routine immunisation vaccine supply, enabling BVNL to initiate technology transfer and begin facility design and construction (Businessday NG, AsheNews).
- Facility Ramp-up: Scheduled groundbreaking for the greenfield vaccine production plant in Ota before Q2 2023 (Businessday NG, AsheNews).
- Strategic Board Inauguration: Formed a capable board in 2018—including experts from the Federal Ministry of Health and May & Baker leadership—responsible for operational oversight and strategic execution (The Guardian Nigeria, Premium Times Nigeria).
Results
- Regulatory Milestone: Secured formal government approval to begin local vaccine production—an essential regulatory stepping-stone (Businessday NG, AsheNews).
- Increased Local Production Readiness: Progressed from planning to actual site preparation, design, and expected groundbreaking—advancing toward operational capacity in vaccine manufacturing.
- Reactivation of Legacy Assets: Brought renewed life to Nigeria’s vaccine production heritage and infrastructure through BVNL’s revived efforts.
Key Metrics
- Formation Year: 2005 (BVNL incorporation as JV) (may-baker.com, LinkedIn)
- Ownership Split: May & Baker Nigeria Plc (51%) and Federal Government of Nigeria (49%) (may-baker.com, Premium Times Nigeria)
- Milestones:
- Board inauguration: 2018 (The Guardian Nigeria)
- MoU approval: September 2022 (Businessday NG, AsheNews)
- Projected groundbreaking: before Q2 2023 (Businessday NG, AsheNews)
Visuals (Suggested Assets)
- Timeline Graphic: Illustrating key milestones—JV formation (2005), board setup (2018), MoU approval (2022), projected groundbreaking (2023).
- Organizational Structure: JV ownership pie chart (51% May & Baker, 49% Federal Government).
- Vision Statement Overlay: Highlighting BVNL’s mission—”Produce safe, affordable vaccines; support Regional manufacturing hub.”
